Combined company will deliver technology, business, and distribution services to community cancer practices, one of the fastest-growing segments in healthcare.
Slideshow: Healthcare Innovators
(click image for larger view and for full slideshow)
McKesson Corporation will acquire U.S. Oncology, a leading integrated oncology company, in an all-cash deal valued at $2.16 billion. The combined organization will focus on providing a comprehensive offering of solutions for the oncology industry, one of the fastest-growing segments in healthcare.
McKesson, a San Francisco, Calif.-based healthcare services and IT company, said Monday that it expects to finalize the deal by the end of the year, pending regulatory approval. McKesson will assume U.S. Oncology's debt valued at $1.6 billion, which will either be repaid or refinanced.
The combination of both companies will provide oncology customers access to: evidence-based medicine to improve clinical outcomes and enable value-based reimbursement; expanded clinical expertise, clinical research, and personalized medicine; integrated healthcare IT, including the iKnowMed and Lynx technology platforms; practice-management solutions and consultative capabilities; and distribution and supply-chain expertise.
John Hammergren, chairman and CEO at McKesson, said his company is committed to improving the way healthcare providers deliver care to patients, and noted that both companies possess the necessary technology and business expertise to make a difference in cancer care.
"The combination of U.S. Oncology and McKesson will enhance our ability to achieve these goals in one of the most important segments in healthcare," Hammergren said in a statement. "Community oncology practices need strategic support that offers not only technology and distribution solutions, but also value-added clinical and reimbursement management services that enable them to provide the highest-quality, most efficient care to their patients. With this acquisition, McKesson will offer a compelling suite of services and solutions to community oncologists and other partners in the rapidly evolving specialty business."